poster

Relationship Between Patient Characteristics, Patterns of Treatment, and Medication Adherence Among Individuals with Major Depressive Disorder

Abstract: Background: Major depressive disorder (MDD) is associated with elevated health care and societal cost, increased morbidity and mortality, and diminished quality of life. First l...

01/19/2023

Long-Term Lumateperone Treatment in Bipolar Disorder: Six-Month Open-label Extension Study

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder. A recent Phase 3 trial...

01/19/2023

Efficacy of Lower-Sodium Oxybate in the Treatment of Idiopathic Hypersomnia: Evaluation of Response Based on the Epworth Sleepiness Scale Score

Abstract: Introduction: This post hoc analysis evaluated response to open-label lower-sodium oxybate (LXB; Xywav®) treatment on Epworth Sleepiness Scale (ESS) scores in a phase 3 clinical...

01/19/2023

Efficacy of Lower-Sodium Oxybate in the Treatment of Idiopathic Hypersomnia: Evaluation of Response Based on the Idiopathic Hypersomnia Severity Scale Score

Abstract: Introduction: This post hoc analysis evaluated response to lower-sodium oxybate (LXB; Xywav®) treatment on Idiopathic Hypersomnia Severity Scale scores in a phase 3 clinical tri...

01/19/2023

Serdexmethylphenidate/Dexmethylphenidate Effects on Sleep in Children With Attention-Deficit Hyperactivity Disorder

Abstract: Aim: To determine sleep behavior during serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) treatment in children with attention-deficit hyperactivity disorder (ADHD). Method...

01/19/2023

Treatment Patterns among Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior Initiated on Esketamine or Traditional Therapies in the United States

Abstract: BACKGROUND: Treatment patterns among adults with major depressive disorder with suicidal ideation or behavior (MDSI) started on esketamine or traditional therapies were describe...

01/19/2023

Esketamine Use among Patients with Treatment-resistant Depression Initiating Esketamine and Completing Induction in the United States

Abstract: BACKGROUND: Access to esketamine therapy for treatment-resistant depression (TRD) is available only through certified treatment centers in the US. Therapy starts with induction ...

01/19/2023

Sustained Treatment Response with Long-Term Valbenazine in Patients with Tardive Dyskinesia

Abstract: Background: Valbenazine is a once-daily VMAT2 inhibitor approved for the treatment of tardive dyskinesia (TD). Data from a 48-week, open-label study of valbenazine (KINECT 4 [NC...

01/19/2023

Aripiprazole plasma concentrations delivered from two 2-month long-acting injectable formulations: an indirect comparison

Abstract: Background: Aripiprazole 2-month ready-to-use 960 mg (2MRTU 960) is a new formulation of aripiprazole monohydrate intended for the treatment of schizophrenia or maintenance mono...

01/19/2023

Long-term safety and Effectiveness of Lurasidone in Adolescents and Young Adults With Schizophrenia: Pooled Post-hoc Analyses of Two 12-month Extension Studies

Abstract: Introduction: The aim of this pooled analysis was to evaluate the long-term safety and effectiveness of lurasidone in the treatment of schizophrenia in adolescents (13-17 years)...

01/19/2023

Tracks

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

Schizophrenia Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products